Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic pancreatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a

Read the full 347 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE